MindMed Q2 net loss $17.1M; Phase 2b LSD trial for GAD on track; reverse split 1-for-15

Definium Therapeutics, Inc.

2022-Q2 EPS reported -$0.08

Q2 2022 net loss $17.1M vs $44.5M in Q2 2021; R&D expense $9.3M (up $1.2M YoY).
Cash $105.7M as of June 30, 2022; runway through key clinical readouts into 2024.
Phase 2b MM-120 (LSD) trial for GAD underway; first patient dosing expected Q3 2022, topline late 2023.
Board approved 1-for-15 reverse share split effective Aug 26, 2022; split-adjusted trading Aug 29.
Appointed Drs. Suzanne Bruhn and Roger Crystal as independent directors; Miri Halperin Wernli retired from board.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Miri Halperin Wernli

Director

DFTX · Definium Therapeutics, Inc.

Effective: 2022-08-11
Successor: Suzanne Bruhn
Filed: August 11, 2022, 7:59 PM ET

On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022.

Appointed

Suzanne Bruhn

Director

DFTX · Definium Therapeutics, Inc.

Effective: 2022-08-11
Filed: August 11, 2022, 7:59 PM ET

On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miri Halperin Wernli resigned as Director at Definium Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Suzanne Bruhn was appointed as Director at Definium Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-016842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.